Molecular and Treatment Characteristics of SMARCB1 or SMARCA4-Deficient Undifferentiated Tumor: Retrospective Case Series

Article information

Cancer Res Treat. 2024;56(3):967-971
Publication date (electronic) : 2024 February 13
doi :
1Seoul National University College of Medicine, Seoul, Korea
2Department of Pathology, Seoul National University Hospital, Seoul, Korea
3Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea
4Department of Otorhinolaryngology, Seoul National University Hospital, Seoul, Korea
Correspondence: Bhumsuk Keam, Department of Internal Medicine, Seoul National University Hospital, 101 Daehak-ro, Jongno-gu, Seoul 03080, Korea Tel: 82-2-2072-7215 Fax: 82-2-2072-7379 E-mail:
Received 2023 December 11; Accepted 2024 February 9.


SMARCB1 or SMARCA4-deficient sinonasal carcinoma or thoracic undifferentiated tumor has aggressive nature with a poor prognosis. Patients with this disease were diagnosed by immunohistochemistry or next-generation sequencing. Those who were able to receive a surgery tended to be cured, while the others treated with chemotherapy, radiation therapy, or immune checkpoint inhibitor were often insensitive to these therapies. However, one having CD274 (PD-L1) amplification showed the response to immune checkpoint inhibitor and a good prognosis. We believed that this report could provide promising information for determining the optimal treatment option.


The SWI/SNF chromatin remodeling complexes regulate DNA transcription and have roles in DNA-damage repair. They act as tumor suppression genes due to their ability to suppress the development of certain cancers when functioning properly, as mutations in these complexes can contribute to cancer initiation and progression [1]. The loss of SMARCB1 or SMARCA4 subunits of SWI/SNF complexes, found in rare cases of sinonasal or thoracic cancer, has been recognized as a significant finding that makes the nature of this cancer more aggressive and the prognosis worse. Early detection and initiation of induction chemotherapy may help improve the prognosis [2,3]. Various regimens of chemotherapy and multimodality treatments are being explored. However, the absence of a standard therapy regimen remains a challenge [4,5]. Furthermore, the impact of genetic variants in cancer cells on therapy outcomes is not well known. Here, we reported our cases of SMARCB1 or SMARCA4-deficient sinonasal carcinoma or thoracic undifferentiated tumor with next-generation sequencing (NGS) data. The objective of this study was to investigate potential directions for optimizing treatment and improving the prognosis of this challenging disease.

Case Report

Six patients with SMARCB1 or SMARCA4-deficient sinonasal carcinoma and three patients with SMARCA4-deficient thoracic undifferentiated tumor were diagnosed from 2021 to 2023. Detailed clinicopathologic features were summarized in Table 1. The deficiency of SMARCB1 or SMARCA4 was defined by NGS or immunohistochemistry (IHC) of SMARCB1 (INI-1) or SMARCA4 (BRG1) loss. Patient 1, 2, and 3 received a surgery. For the unresectable cases, definitive concurrent chemoradiotherapy with or without induction chemotherapy was done. In the case of patient 4 and 6, cisplatin treatment suppressed the disease progression. Patient 1 and 2 who had been diagnosed as olfactory neuroblastoma got the revision of the diagnosis after IHC revealing BRG1 loss. NGS was conducted in five patients. Patient 9, who exhibited CD274 gene amplification and was associated with a programmed death-ligand 1 (PD-L1) IHC positivity (22C3, Tumor Proportion Score 90%), experienced a favorable prognosis when treated with an immune checkpoint inhibitor (ICI), durvalumab. This CD274-amplified patient showed partial response and progression free survival of more than 17 months (Fig. 1).

Clinicopathological features of patients with SMARCB1 or SMARCA4-deficient sinonasal carcinoma or thoracic undifferentiated tumor including next-generation sequencing data

Fig. 1.

Clinical response to durvalumab in CD274-amplified patient with SMARCA4-deficient thoracic undifferentiated tumor. Initial computed tomography (CT) image before therapy (A). CT image after concurrent chemoradiation (B). Follow-up CT image after treating with consolidation durvalumab 13 cycles (C).


In our case series, SMARCB1 or SMARCA4-deficient sinonasal carcinoma or thoracic undifferentiated tumor presented the advanced stage when initially diagnosed, and showed the rapid progression leading to a poor prognosis. However, some patients, especially with CD274 (PD-L1) amplification, showed a good response to ICI, suggesting that ICI could be a treatment option for this rare disease. We could diagnose the deficiency of SMARCB1 or SMARCA4 using NGS or IHC of INI-1 or BRG1.

When the patients were diagnosed as locally advanced setting, multi-disciplinary treatments including surgery, radiation therapy, chemotherapy and ICI were important. Within this group, a subset of patients achieved no evidence of disease. Although another case series reported that patients with SMARCA4-deficient sinonasal carcinoma experienced poor outcomes following surgery [6], our patients who underwent upfront surgery displayed a favorable prognosis compared to others. Adjuvant radiation therapy after surgery potentially contributed to improved overall survival [7].

Taxane in combination with platinum was the preferred regimen in our case series, similar to the major treatment option for sinonasal malignancies in other studies [8]. Some studies demonstrated the resistance to chemotherapy and radiation therapy, especially the ineffectiveness of platinum therapy for SMARCA4-deficient undifferentiated tumor [9,10]. In our case series, several patients showed the insensitivity to these therapies, while a subset of the patients exhibited clinical responses. Additionally, we observed promising effects of ICI in some cases [11-13], with two patients receiving this therapy displaying contrasting responses. In NGS findings, most patients showed negative microsatellite instability and low tumor mutation burden, indicating a lower likelihood of responding to ICI. However, one patient exhibited CD274 amplification with PD-L1 overexpression and displayed the response to ICI. Notably, CD274 amplification in cancer cells might indicate the sensitivity to ICI, making this finding significant for guiding therapeutic planning and potentially leading to a more favorable prognosis [14,15].

Nevertheless, given the limited sample size of our report and the lack of data such as NGS study only conducted on a subset of the patients, it is essential to conduct further in-depth studies with a larger sample size to validate and elucidate the nature of this rare disease fully.

In conclusion, due to the potential implications of SMARCB1 or SMARCA4 loss in sinonasal or thoracic cancer, it is crucial to gain a comprehensive understanding of the underlying pathophysiology and consider prompt evaluation using IHC or NGS techniques. NGS, in particular, allows for the identification of several key gene variations, such as PD-L1 amplification, which can significantly impact the efficacy of the therapy. This knowledge can aid in tailoring the most optimal treatment regimen for each patient, ultimately leading to improved therapeutic outcomes.


Ethical Statement

The study protocol was approved by the Institutional Review Board of Seoul National University Hospital (approval number: H-2307-026-1446) and was conducted in accordance with the Principles of the Declaration of Helsinki. Informed consents were waived from IRB, because this study was retrospective analysis with minimal risk.

Author Contributions

Conceived and designed the analysis: Kang HG, Keam B.

Collected the data: Kang HG, Koh J, Kim TM, Han DH, Won TB, Kim DW, Kim DY, Keam B.

Contributed data or analysis tools: Kang HG, Keam B.

Performed the analysis: Kang HG, Keam B.

Wrote the paper: Kang HG, Koh J, Kim TM, Han DH, Won TB, Kim DW, Kim DY, Keam B.

Conflicts of Interest

The authors certified that they have no conflict of interest (COI) directly related to this report. Broad information about their COI is presented.

BK received research funding from MSD, AstraZeneca, and Ono Pharmaceutical Co., Ltd., and has served as an advisor for Handok, NeoImmuneTec, Trialinformatics and ImmuneOncia outside of the current work.

TMK received consulting or advisory from Amgen, AstraZeneca/MedImmune, Bayer, Boryung, Hanmi, IMBDx, Inc., Janssen, Novartis, Regeneron, Roche/Genentech, Samsung Bioepis, Sanofi, and Takeda outside of the current work.

DWK received clinical trial research funding from Alpha Biopharma, Amgen, Astrazeneca/Medimmune, Boehringer-Ingelheim, Bridge BioTherapeutics, Chong Keun Dang, Daiichi-Sankyo, GSK, Hanmi, Janssen, Merck, Merus, Mirati Therapeutics, MSD, Novartis, ONO Pharmaceutical, Pfizer, Roche/Genentech, Takeda, TP Therapeutics, Xcovery, and Yuhan outside of the current work.


1. Mittal P, Roberts CW. The SWI/SNF complex in cancer: biology, biomarkers and therapy. Nat Rev Clin Oncol 2020;17:435–48.
2. Agaimy A, Hartmann A, Antonescu CR, Chiosea SI, El-Mofty SK, Geddert H, et al. SMARCB1 (INI-1)-deficient sinonasal carcinoma: a series of 39 cases expanding the morphologic and clinicopathologic spectrum of a recently described entity. Am J Surg Pathol 2017;41:458–71.
3. Haberecker M, Buhler MM, Mendieta AP, Guggenberger R, Arnold F, Markert E, et al. Molecular and immunophenotypic characterization of SMARCB1 (INI1)-deficient intrathoracic neoplasms. Mod Pathol 2022;35:1860–9.
4. Contrera KJ, Shakibai N, Su SY, Gule-Monroe MK, Roberts D, Brahimaj B, et al. Impact of clinical factors and treatments on SMARCB1 (INI-1)-deficient sinonasal carcinoma. Otolaryngol Head Neck Surg 2023;169:435–40.
5. Lee VH, Tsang RK, Lo AW, Chan SY, Chung JC, Tong CC, et al. SMARCB1 (INI-1)-deficient sinonasal carcinoma: a systematic review and pooled analysis of treatment outcomes. Cancers (Basel) 2022;14:3285.
6. Agaimy A, Jain D, Uddin N, Rooper LM, Bishop JA. SMARCA4-deficient sinonasal carcinoma: a series of 10 cases expanding the genetic spectrum of SWI/SNF-driven sinonasal malignancies. Am J Surg Pathol 2020;44:703–10.
7. Wang R, Wang L, Fang J, Zhong Q, Hou L, Ma H, et al. Clinical diagnosis and treatment analyses on SMARCB1 (integrase interactor 1)-deficient sinonasal carcinoma: case series with systematic review of the literature. World Neurosurg 2022;161:e229–43.
8. Thawani R, Kim MS, Arastu A, Feng Z, West MT, Taflin NF, et al. The contemporary management of cancers of the sinonasal tract in adults. CA Cancer J Clin 2023;73:72–112.
9. Nambirajan A, Jain D. Recent updates in thoracic SMARCA4-deficient undifferentiated tumor. Semin Diagn Pathol 2021;38:83–9.
10. Bell EH, Chakraborty AR, Mo X, Liu Z, Shilo K, Kirste S, et al. SMARCA4/BRG1 is a novel prognostic biomarker predictive of cisplatin-based chemotherapy outcomes in resected non-small cell lung cancer. Clin Cancer Res 2016;22:2396–404.
11. Takada K, Sugita S, Murase K, Kikuchi T, Oomori G, Ito R, et al. Exceptionally rapid response to pembrolizumab in a SMARCA4-deficient thoracic sarcoma overexpressing PD-L1: a case report. Thorac Cancer 2019;10:2312–5.
12. Shi L, Lin L, Ding Y, Zeng Y, Chen X. Case report: a rapid response to immunotherapy in a thoracic SMARCA4-deficient undifferentiated tumor with respiratory failure. Front Oncol 2022;12:1020875.
13. Henon C, Blay JY, Massard C, Mir O, Bahleda R, Dumont S, et al. Long lasting major response to pembrolizumab in a thoracic malignant rhabdoid-like SMARCA4-deficient tumor. Ann Oncol 2019;30:1401–3.
14. George J, Saito M, Tsuta K, Iwakawa R, Shiraishi K, Scheel AH, et al. Genomic amplification of CD274 (PD-L1) in smallcell lung cancer. Clin Cancer Res 2017;23:1220–6.
15. Inoue Y, Suda T, Sugimura H. CD274 (PD-L1) genomic change: another marker for small cell lung cancer? Transl Cancer Res 2017;6(Suppl 1):S33–5.

Article information Continued

Fig. 1.

Clinical response to durvalumab in CD274-amplified patient with SMARCA4-deficient thoracic undifferentiated tumor. Initial computed tomography (CT) image before therapy (A). CT image after concurrent chemoradiation (B). Follow-up CT image after treating with consolidation durvalumab 13 cycles (C).

Table 1.

Clinicopathological features of patients with SMARCB1 or SMARCA4-deficient sinonasal carcinoma or thoracic undifferentiated tumor including next-generation sequencing data

Patient No. Age (yr)/Sex Diagnosis Initial stage IHC Variant gene Variant type Variant detail Tier MSI TMB_alpha Treatment summary CT regimen BR Clinical course OS
1 47/ F ON→SNC pT4bNxM0 BRG1(–) SMARCA4 SNV Q915* Not reported Surgery+PO CCRT Cisplatin (–) NED 10.4+
TET2 SNV R1451fs
2 50/M ON→SNC pTxN2bM0 BRG1(–) NGS not conducted Surgery+PORT (–) (–) NED 5.6+
3 77/M SNC pT2N0M0 INI-1(–) NGS not conducted Surgery+PORT (–) (–) NED 19.2+
4 76/M SNC cT3aN0M0 INI-1(–) NGS not conducted IC+dCCRT DP PR CR 11.4+
Cisplatin CR
5 86/M SNC cT4bN0M0 INI-1(–) SMARCB1 CNV CN 1 copy D MSS 2.13 pRT (–) PD Death 10.4
6 68/M SNC cT4aN0M0 INI-1(–) SMARCB1 CNV CN 0 copy C MSS 7.46 IC+dCCRT DPF PD AWD 3.6+
P40(–) Cisplatin SD
7 74/M TUT cT4N2M0/1 BRG1(–) NGS not conducted pCT+ICI TC PD Death 3.3
P40(–) Pembro PD
8 52/M TUT cT4N2M1 BRG1(–) SMARCA4 SNV V318fs D MSS 5.33 pCT TC PD death 3.4
P40(–) ARID1A SNV D179Y C
TP53 SNV Q204* D
9 72/M TUT cT4N3M0 P40(–) SMARCA4 SNV R704fs D MSS 8.52 dCCRT+ICI TC durva PR AWD 17.0+
PD-L1(90%) ARID1B SNV Q124_Q131del C PR
TP53 SNV R335fs D
CD274 CNV CN 6 copy D
FGFR1 CNV CN 6 copy D
JAK2 CNV CN 7 copy D
PDCD1LG2 CNV CN 6 copy D

AWD, alive with disease; BR, best response; CN, copy number; CNV, copy number variant; CR, complete response; CT, chemotherapy; dCCRT, definitive concurrent chemoradiation therapy; del, deletion; DP, docetaxel+cisplatin; DPF, docetaxel+cisplatin+5-FU; durva, durvalumab; fs, frame shift; IC, induction chemotherapy; ICI, immune checkpoint inhibitor; IHC, immunohistochemistry; MSI, microsatellite instability; MSS, microsatellite stability; NED, no evidence of disease; NGS, next-generation sequencing; ON, olfactory neuroblastoma; OS, overall survival; pCT, palliative chemotherapy; PD, progression of disease; PD-L1, programmed death-ligand 1; pembro, pembrolizumab; PO CCRT, post-operative concurrent chemoradiation therapy; PORT, post-operative radiation therapy; PR, partial response; pRT, palliative radiation therapy; SD, stable disease; SNC, sinonasal carcinoma; SNV, single nucleotide variant; TC, paclitaxel+carboplatin; TMB, tumor mutation burden; TUT, thoracic undifferentiated tumor.